LAUSR

Background: Due to the heterogeneity of soft tissue sarcomas, conflicting data have been reported regarding treatment outcomes. Moreover, factors such as histologic subtype, treatment compliance, and treatment tolerability may influence outcomes of treatment. The aim of this study was to investigate the clinical characteristics, prognostic factors, survival outcomes, and outcomes of treatment in patients with extremity soft tissue sarcoma who underwent complete tumor resection at Siriraj Hospital. Methods: Medical records of patients with extremity soft tissue sarcoma underwent total tumor resection at Siriraj Hospital during the January 2007 to December 2016 study period were included. Data collected included demographic data, tumor characteristics, type of surgery, and postsurgical intervention. Regimen, dose, cycle, and treatment compliance data were collected in patients who received adjuvant chemotherapy. Results: A total of 58 patients with a median age of 53.5 years were included. In total, 13 patients received adjuvant chemotherapy. Tumor grade 3 with size >10 cm was a baseline factor found to be a significant predictor of unfavorable disease-free survival (DFS) ( p <0.001). Median DFS was 56.2 months in the chemotherapy group and 20.5 months in the non-chemotherapy group ( p =0.29). Median OS was 77.2 months in the chemotherapy group and 66.6 months in the non-chemotherapy group ( p =0.24). A total of 20% of patients in chemotherapy group developed grade 3-4 hematologic toxicity. Conclusion: Tumor grade 3 >10 cm was the only baseline characteristic found to be a significant predictor of unfavorable DFS in univariate analysis. No conclusive benefit of adjuvant chemotherapy in term of DFS and OS.